Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
WuXi AppTec and MedImmune, an AstraZeneca subsidiary,...
3SBio Inc. of Shenyang has agreed to be bought by Dr....
Cardinal Health, a US drug distributor, spent $120...
3SBio received a much-higher offer from the consortium...
Syros Pharmaceuticals of Boston raised $30 million to...
3SBio Inc. rescheduled the shareholders meeting that will...
Shanghai Fosun Pharma, Chindex and a private equity...
3SBio Inc. will go private. A full 87% of company's...
Zhejiang Hisun Pharma contributed 75 drug products to...
CBT 200 Gains 34 Points. More details...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
